Benefits
Plasmacytoid dendritic cell activation (immune marker)
LC-Plasma uniquely activates pDCs — the innate immune cells most specialized for antiviral defense. Both live and heat-killed forms induce IFN-α production. An individual-participant meta-analysis (619 participants) found LC-Plasma kept the pDC activation markers CD86 and HLA-DR higher than placebo. These are laboratory measures of immune-cell activity, not proof of fewer or shorter colds; the clinical symptom effect rests on the separate symptom analysis, not on these markers.
Reduced cold-like symptom days
A meta-analysis of eight manufacturer-funded RCTs (555 participants) found that daily LC-Plasma modestly reduced two of four tracked cold-like symptoms: cough, by about 0.7 fewer days per 28 days, and feverishness, by about 0.3 fewer days. Sore throat and runny nose were not significantly reduced. The effect is small and every trial comes from one company (Kirin).
Type I interferon induction (laboratory marker)
In a laboratory comparison of five postbiotic products, only LC-Plasma was taken up by cultured pDCs and induced measurable interferon-alpha (73.8 pg/mL in the assay). This is an in-vitro marker of immune-cell activity, not a level measured in the blood of people who took the product, and it does not by itself show protection against any infection. Other tested strains produced no interferon-alpha response.
Postbiotic stability advantage
As a heat-killed paraprobiotic/postbiotic, LC-Plasma doesn't require cold-chain storage or live-cell viability. The activity is preserved through normal manufacturing and remains effective when incorporated into shelf-stable foods, beverages, and supplements — a practical advantage over conventional live probiotics for immune support.
Mechanism of action
TLR9 / pDC pathway activation
LC-Plasma is uniquely phagocytosed by plasmacytoid dendritic cells (pDCs) — a relatively rare immune cell population specialized for sensing viral nucleic acids and producing massive amounts of type I interferons. Most lactic acid bacteria activate myeloid DCs, not pDCs. LC-Plasma's distinctive cell wall components engage TLR9 and other intracellular pattern recognition receptors.
Type I interferon (IFN-α/β) cascade
Activated pDCs secrete IFN-α/β, which establish an antiviral state in surrounding cells: upregulating MHC class I, activating NK cells, priming cytotoxic T lymphocytes, and inducing antiviral effector proteins (PKR, OAS, Mx). This is the proposed antiviral mechanism. It is a laboratory and cell-signaling rationale and has not been shown to prevent infection by any specific virus in people.
Mucosal immune priming
Oral consumption of LC-Plasma provides direct contact with gut-associated lymphoid tissue (GALT), where pDCs can be activated and migrate to draining lymph nodes. This may explain the systemic immune effects from oral administration despite the heat-killed status precluding gut colonization.
Clinical trials
Individual participant data pooled analysis (Frontiers in Immunology, doi:10.3389/fimmu.2025.1696989).
Clinical trials of oral LC-Plasma vs placebo in healthy adults. Searches through across PubMed, Cochrane, J-Dream III, UMIN-CTR, and ICTRP.
Across eight Kirin-funded RCTs, pDC activation markers CD86 and HLA-DR stayed higher than placebo (619 participants). For symptoms (555 participants), only cough (about 0.7 fewer days per 28 days) and feverishness (about 0.3 fewer days) were significantly reduced; sore throat and runny nose were not. Authors concluded daily LC-Plasma may sustain pDC activation and reduce cough and feverishness. The clinical effect is small and all trials come from a single manufacturer.
Randomized, placebo-controlled, double-blind trial (Sugimura, Jounai, Ohshio, Tanaka, Suwa, Clin Immunol 149(3):509-518).
Healthy adult volunteers consuming yogurt fermented with L. lactis JCM5805 (LC-Plasma) vs placebo yogurt for 12 weeks.
Yogurt containing LC-Plasma activated pDC activity in vivo (peripheral blood pDC CD86 and HLA-DR expression). Effect was greater in subjects with low baseline pDC activity. IFN production capacity increased from baseline. Common cold morbidity risk was suppressed in the LC-Plasma group vs placebo. Established the foundational case that LC-Plasma activates pDCs in humans, not just in vitro.
Comparative postbiotic mechanism study (2025).
Five commercially available postbiotic products containing heat-killed bacterial strains tested for pDC activation and IFN-α induction. Confocal Z-stack imaging used to confirm bacterial internalization.
This was a laboratory (in-vitro) comparison, not a study in people. Among 5 tested postbiotic strains, only LC-Plasma was internalized by cultured pDCs and induced measurable interferon-alpha (73.8 pg/mL in the assay). Other strains showed no response even at higher loads. These are cell-culture markers; the study did not measure colds, infections, or any clinical outcome.